Leerink Partnrs Reduces Earnings Estimates for Cytokinetics

Cytokinetics, Incorporated (NASDAQ:CYTK) – Stock analysts at Leerink Partnrs decreased their Q2 2025 earnings per share estimates for shares of Cytokinetics in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst R. Ruiz now forecasts that the biopharmaceutical company will earn ($1.34) per share for the quarter, down from their prior estimate of ($1.32). The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. Leerink Partnrs also issued estimates for Cytokinetics’ Q3 2025 earnings at ($1.41) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($5.69) EPS, FY2026 earnings at ($5.25) EPS, FY2027 earnings at ($3.90) EPS and FY2028 earnings at ($0.95) EPS.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.41) by $0.05. The company had revenue of $1.60 million during the quarter, compared to the consensus estimate of $2.77 million. The company’s quarterly revenue was up 89.1% on a year-over-year basis. During the same quarter last year, the firm posted ($1.33) earnings per share.

Other analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of Cytokinetics in a research note on Monday, April 21st. Bank of America decreased their target price on Cytokinetics from $62.00 to $54.00 and set a “neutral” rating for the company in a research note on Tuesday, April 15th. Citigroup dropped their price objective on shares of Cytokinetics from $86.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday. Barclays decreased their price target on shares of Cytokinetics from $55.00 to $53.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 target price on shares of Cytokinetics in a research report on Friday, May 2nd. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $74.44.

Cytokinetics Stock Performance

Cytokinetics stock opened at $31.69 on Friday. The business’s 50-day moving average price is $40.18 and its two-hundred day moving average price is $46.01. The stock has a market cap of $3.78 billion, a PE ratio of -5.89 and a beta of 0.81. Cytokinetics has a 12-month low of $31.67 and a 12-month high of $64.61. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93.

Insider Activity at Cytokinetics

In other news, EVP Fady Ibraham Malik sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $45.98, for a total value of $91,960.00. Following the transaction, the executive vice president now owns 116,071 shares in the company, valued at approximately $5,336,944.58. This represents a 1.69 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Andrew Callos sold 3,341 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07. Following the sale, the executive vice president now directly owns 64,434 shares of the company’s stock, valued at $2,788,059.18. This trade represents a 4.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 95,362 shares of company stock valued at $3,899,118 in the last 90 days. Corporate insiders own 2.70% of the company’s stock.

Institutional Trading of Cytokinetics

Several institutional investors have recently added to or reduced their stakes in CYTK. Harbor Capital Advisors Inc. raised its stake in shares of Cytokinetics by 6.1% in the fourth quarter. Harbor Capital Advisors Inc. now owns 45,130 shares of the biopharmaceutical company’s stock worth $2,123,000 after purchasing an additional 2,604 shares during the last quarter. Mirador Capital Partners LP increased its holdings in Cytokinetics by 1.6% in the 4th quarter. Mirador Capital Partners LP now owns 65,636 shares of the biopharmaceutical company’s stock worth $3,088,000 after buying an additional 1,010 shares in the last quarter. Inspire Investing LLC raised its position in Cytokinetics by 7.8% in the 4th quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company’s stock worth $400,000 after buying an additional 616 shares during the last quarter. Blue Trust Inc. lifted its stake in Cytokinetics by 85.8% during the 4th quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 842 shares during the period. Finally, Pacer Advisors Inc. boosted its holdings in shares of Cytokinetics by 2.9% during the 4th quarter. Pacer Advisors Inc. now owns 24,843 shares of the biopharmaceutical company’s stock valued at $1,169,000 after acquiring an additional 690 shares during the last quarter.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.